Journal Club: Dr Mehbub Shafi reviewing the VOYAGE 2 clinical trial

For our next session of Journal Club we welcome guest host Dr Mehbub Shafi.

Mehbub has chosen to review:

‘Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatorecontrolled VOYAGE 2 trial.’

Reich et al (2016) J Am Acad Dermatol
http://dx.doi.org/10.1016/j.jaad.2016.11.042 

“For my review, I chose to focus on Psoriasis, a condition in which I have personal insight, including its effect on patients both clinically and psycho-socially. The paper I chose to review was the VOYAGE 2 clinical trial. (Efficacy and safety of Guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator controlled VOYAGE 2 trial)”